MA34581B1 - Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner) - Google Patents

Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner)

Info

Publication number
MA34581B1
MA34581B1 MA35706A MA35706A MA34581B1 MA 34581 B1 MA34581 B1 MA 34581B1 MA 35706 A MA35706 A MA 35706A MA 35706 A MA35706 A MA 35706A MA 34581 B1 MA34581 B1 MA 34581B1
Authority
MA
Morocco
Prior art keywords
release liner
transdermal therapeutic
therapeutic systems
protective sheet
inhibiting crystallization
Prior art date
Application number
MA35706A
Other languages
English (en)
Inventor
Stefan Bracht
Ildiko Terebesi
Thomas Langguth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34581(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34581B1 publication Critical patent/MA34581B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

L'invention concerne des formulations pharmaceutiques, en particulier des systèmes thérapeutiques transdermiques, qui sont caractérisées en ce qu'aucun principe actif n'est éliminé par cristallisation à l'interface entre feuille de protection enlevable (release liner) et matrice contenant le principe actif. En ce qui concerne le principe actif, il s'agit de gestodène ou d'un ester de gestodène dans le polymère matriciel sursaturé et/ou d'éthinylestradiol. La matrice est exempte de promoteurs de solubilité, d'inhibiteurs de cristallisation et d'agents de dispersion.
MA35706A 2010-09-06 2011-09-02 Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner) MA34581B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
PCT/EP2011/065204 WO2012031985A1 (fr) 2010-09-06 2011-09-02 Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner)

Publications (1)

Publication Number Publication Date
MA34581B1 true MA34581B1 (fr) 2013-10-02

Family

ID=44653285

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35706A MA34581B1 (fr) 2010-09-06 2011-09-02 Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner)

Country Status (32)

Country Link
US (2) US8557279B2 (fr)
EP (1) EP2613771A1 (fr)
JP (2) JP6104800B2 (fr)
KR (1) KR20130114127A (fr)
CN (1) CN103079549B (fr)
AP (1) AP3586A (fr)
AR (1) AR082907A1 (fr)
AU (1) AU2011298892B2 (fr)
BR (1) BR112013005305A2 (fr)
CA (1) CA2810103C (fr)
CL (1) CL2013000636A1 (fr)
CO (1) CO6690753A2 (fr)
CR (1) CR20130098A (fr)
CU (1) CU24172B1 (fr)
DE (1) DE102010040299A1 (fr)
DO (1) DOP2013000053A (fr)
EA (1) EA032575B1 (fr)
EC (1) ECSP13012477A (fr)
GT (1) GT201300062A (fr)
IL (2) IL224980A (fr)
MA (1) MA34581B1 (fr)
MX (1) MX2013002602A (fr)
MY (1) MY162768A (fr)
NZ (1) NZ607630A (fr)
PE (2) PE20131138A1 (fr)
SG (2) SG187941A1 (fr)
TN (1) TN2013000087A1 (fr)
TW (1) TWI576245B (fr)
UA (1) UA110217C2 (fr)
UY (1) UY33590A (fr)
WO (1) WO2012031985A1 (fr)
ZA (1) ZA201301389B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (fr) * 1987-04-02 1990-06-29 Ciba Geigy Ag
EP0370220B1 (fr) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Composition de Gestoden à application transdermique
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
CA2091883A1 (fr) 1990-10-29 1992-04-30 Robert M. Gale Compositions contraceptives transdermiques, methodes et instruments
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
JP4841781B2 (ja) 1999-11-24 2011-12-21 アジル・セラピューティクス・インコーポレイテッド 改良された経皮的避妊薬送達系および方法
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
WO2002045701A2 (fr) 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation
EP1216699A1 (fr) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Système transdermique comprenant un progestatif très puissant
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
RS50428B (sr) * 2003-02-21 2009-12-31 Bayer Schering Pharma Aktiengesellschaft, Uv-stabilni transdermalni flasteri
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
KR101168449B1 (ko) * 2003-12-12 2012-07-25 바이엘 파마 악티엔게젤샤프트 침투 증진인자가 필요없는 호르몬의 경피 전달계
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
JP2012504609A (ja) * 2008-10-06 2012-02-23 マイラン・テクノロジーズ，インコーポレイテッド アモルファスロチゴチン経皮システム

Also Published As

Publication number Publication date
EA032575B1 (ru) 2019-06-28
AP3586A (en) 2016-02-10
IL224980A (en) 2017-07-31
WO2012031985A1 (fr) 2012-03-15
CR20130098A (es) 2013-05-15
JP2013536828A (ja) 2013-09-26
BR112013005305A2 (pt) 2016-08-16
EA201390246A1 (ru) 2013-09-30
ZA201301389B (en) 2021-05-26
AR082907A1 (es) 2013-01-16
MY162768A (en) 2017-07-14
US9060955B2 (en) 2015-06-23
IL251124A0 (en) 2017-04-30
GT201300062A (es) 2015-01-16
AU2011298892A1 (en) 2013-03-28
TWI576245B (zh) 2017-04-01
AP2013006787A0 (en) 2013-04-30
IL251124B (en) 2020-07-30
KR20130114127A (ko) 2013-10-16
CA2810103A1 (fr) 2012-03-15
CO6690753A2 (es) 2013-06-17
DE102010040299A1 (de) 2012-03-08
CN103079549B (zh) 2016-11-02
UA110217C2 (en) 2015-12-10
NZ607630A (en) 2015-02-27
CU24172B1 (es) 2016-04-25
JP6104800B2 (ja) 2017-03-29
US20140018751A1 (en) 2014-01-16
SG10201506927TA (en) 2015-10-29
CL2013000636A1 (es) 2013-09-13
US8557279B2 (en) 2013-10-15
US20120082714A1 (en) 2012-04-05
PE20180198A1 (es) 2018-01-26
TW201217165A (en) 2012-05-01
PE20131138A1 (es) 2013-10-26
UY33590A (es) 2011-10-31
AU2011298892B2 (en) 2015-03-12
CU20130031A7 (es) 2013-05-31
DOP2013000053A (es) 2013-07-15
CA2810103C (fr) 2019-06-18
MX2013002602A (es) 2013-04-08
ECSP13012477A (es) 2013-04-30
JP2016216500A (ja) 2016-12-22
TN2013000087A1 (en) 2014-06-25
EP2613771A1 (fr) 2013-07-17
SG187941A1 (en) 2013-04-30
CN103079549A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
CA2602573A1 (fr) Agent protecteur pour la cellule neuronale retinienne contenant un derive de prostaglandine f2 .alpha. comme ingredient actif
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
IN2012MN02923A (fr)
WO2011116139A3 (fr) Compositions pharmaceutiques améliorées et procédés d'administration
MY172303A (en) Compositions and methods of use of phorbol esters
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
CL2013003630A1 (es) Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros.
BR112013002280A2 (pt) composições farmacêuticas orais de liberação controlada compreendendo blonanseina
MA38694A2 (fr) Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
MA34581B1 (fr) Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner)
RU2014129620A (ru) Композиции, содержащие аморфный эмодепсид
SA518392325B1 (ar) حمض (2s،4r)-5-(5'-كلورو -2'-فلورو-[1،1'-باي فينيل ]-4-يل )-2-(إيثوكسي ميثيل )-4-(3-هيدروكسي أيزوكسازول -5-كربوكساميدو )-2-ميثيل بنتانويك بلوري واستخداماته
WO2019104207A3 (fr) Compositions et procédés d'utilisation pour traiter une inflammation aberrante dans des glandes sécrétoires périoculaires ou au niveau de la surface oculaire
MA33804B1 (fr) Composition pharmaceutique pour le traitement des brûlures cutanées
FR2987271B1 (fr) Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
WO2011035343A3 (fr) Forme galénique liquide de la phentermine
FR3014692B1 (fr) Compositions pharmaceutiques orales a retention gastrique.
WO2020013781A3 (fr) Effet synergique de flurbiprofène et d'agent protecteur gastrique pour le traitement de la douleur et de l'inflammation